Analysts Set MorphoSys AG (NASDAQ:MOR) PT at $24.88

Shares of MorphoSys AG (NASDAQ:MOR) have been assigned an average rating of “Hold” from the fourteen analysts that are covering the stock, Marketbeat.com reports. Ten equities research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $28.17.

MOR has been the subject of several recent research reports. JPMorgan Chase & Co. reissued a “neutral” rating on shares of MorphoSys in a research note on Wednesday, August 4th. Commerzbank lowered shares of MorphoSys from a “buy” rating to a “hold” rating and set a $59.00 price objective for the company. in a research note on Tuesday, July 27th. Morgan Stanley reissued an “overweight” rating on shares of MorphoSys in a research note on Wednesday, August 4th. Zacks Investment Research lowered shares of MorphoSys from a “strong-buy” rating to a “hold” rating in a research note on Wednesday. Finally, SVB Leerink reaffirmed an “outperform” rating and issued a $13.50 target price on shares of MorphoSys in a report on Tuesday, July 27th.

MOR stock traded up $0.13 during mid-day trading on Friday, hitting $11.70. 1,415 shares of the company were exchanged, compared to its average volume of 78,030. The company has a quick ratio of 6.07, a current ratio of 6.14 and a debt-to-equity ratio of 0.46. The firm has a market capitalization of $1.60 billion, a P/E ratio of -12.56 and a beta of 0.94. The business has a fifty day simple moving average of $13.00 and a 200-day simple moving average of $17.64. MorphoSys has a 12-month low of $11.03 and a 12-month high of $30.75.

MorphoSys (NASDAQ:MOR) last posted its quarterly earnings data on Wednesday, July 28th. The company reported $0.18 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.48) by $0.66. MorphoSys had a negative net margin of 68.05% and a negative return on equity of 16.50%. The business had revenue of $46.06 million during the quarter, compared to analyst estimates of $46.02 million. Research analysts predict that MorphoSys will post -1.78 EPS for the current year.

A number of hedge funds have recently added to or reduced their stakes in MOR. BlackRock Inc. acquired a new stake in MorphoSys during the first quarter worth approximately $73,000. Geneos Wealth Management Inc. acquired a new stake in MorphoSys during the first quarter worth approximately $105,000. Marshall Wace LLP acquired a new position in shares of MorphoSys in the 2nd quarter valued at $199,000. Wells Fargo & Company MN increased its holdings in shares of MorphoSys by 713.2% in the 2nd quarter. Wells Fargo & Company MN now owns 11,491 shares of the company’s stock valued at $221,000 after acquiring an additional 10,078 shares during the period. Finally, Cresset Asset Management LLC acquired a new position in shares of MorphoSys in the 2nd quarter valued at $230,000. 1.71% of the stock is currently owned by institutional investors.

MorphoSys Company Profile

MorphoSys AG engages in the development of antibodies for therapeutic, diagnostics, and research applications. It operates through the Proprietary Development and Partnered Discovery segments. The Proprietary Development segment combines proprietary research and development of therapeutic compounds. The Partnered Discovery segment offers technologies to make human antibody-based therapeutics on behalf of partners in the pharmaceutical industry.

Featured Article: What is a Fiduciary?

Analyst Recommendations for MorphoSys (NASDAQ:MOR)

Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.